Elto Pharma
to Present and Participate in Neuroscience
Panel at Sachs BioCapital USA
Forum
San Francisco, CA -- March
5, 2018 -- InvestorsHub NewsWire -- Elto Pharma, Inc., an orphan
specialty pharmaceutical, clinical-stage wholly-owned subsidiary of
Amarantus Bioscience Holdings,
Inc. (OTCPK:
AMBS),
that is advancing Eltoprazine into a Phase 2b clinical
trial for the treatment of the orphan indication Parkinson's
disease levodopa-induced dyskinesia (PD-LID), today announced that
it will be presenting a summary of its pending Phase 2b PD-LID
clinical program and participating in the neuroscience panel at the
Sachs BioCapital USA Forum on March 21, 2018 at the New York
Academy of Sciences (NYAS) in New York City. The neuroscience panel
is entitled "Renewed Approaches for
Neuroscience."
"Sachs BioCapital USA
Forum is an ideal venue for Elto Pharma to engage with the
investment and partnering community," said Gerald Commissiong,
interim-CEO of Elto Pharma.
Presentation
Details
Company: Elto Pharma
(an Amarantus company)
Event: Sachs
BioCapital USA Forum
Date: Wednesday,
March 21, 2018
Time: 2:20 p.m.
EDT for 20 minutes
Presentation Track: T rack
C
Webcast: Please
check www.amarantus.com for
details prior to the event
Location: New
York Academy of Sciences, New York, NY
About
Elto Pharma, Inc.
Elto Pharma, Inc. is
developing Eltoprazine, an oral small molecule 5HT1A/1B partial
agonist in clinical development for the treatment of Parkinson's
disease levodopa-induced dyskinesia (PD-LID), Alzheimer's
aggression and adult attention deficit hyperactivity disorder
(adult ADHD). Eltoprazine has been evaluated in over 680 human
subjects to date, and has a well-established safety profile, with
statistically significant efficacy results across multiple central
nervous system indications. Eltoprazine has received orphan drug
designation (ODD) from the US FDA for the treatment of
PD-LID.
Eltoprazine was originally
developed by Solvay (now Abbvie) in aggression-related indications.
The eltoprazine program was out-licensed to PsychoGenics, Inc.
(PGI). PGI licensed eltoprazine to Amarantus in 2014 after a
successful proof-of-concept trial in PD-LID.
In April 2017, Amarantus
incorporated the wholly-owned subsidiary Elto Pharma, Inc. to for
the purpose of raising capital to finance the further clinical
development of Eltoprazine.
About Amarantus
Bioscience Holdings, Inc.
Amarantus Bioscience
Holdings (AMBS)
is a biotechnology company developing treatments and diagnostics
for diseases in the areas of neurology, regenerative medicine and
orphan diseases through its subsidiaries. AMBS' wholly-owned
subsidiary Elto Pharma, Inc. has development rights to
eltoprazine, a Phase 2b-ready small molecule indicated for
Parkinson's disease levodopa-induced dyskinesia, Alzheimer's
aggression and adult attention deficit hyperactivity disorder,
commonly known as ADHD. AMBS acquired the rights to the Engineered
Skin Substitute program (ESS), a regenerative medicine-based
approach for treating severe burns with full-thickness autologous
skin grown in tissue culture that is being pursued by AMBS'
wholly-owned subsidiary Cutanogen Corporation. AMBS'
wholly-owned subsidiary MANF Therapeutics, Inc. owns key
intellectual property rights and licenses from a number of
prominent universities related to the development of the
therapeutic protein known as mesencephalic astrocyte-derived
neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is
developing MANF-based products as treatments for brain and
ophthalmic disorders. MANF was discovered by the Company's Chief
Scientific Officer John Commissiong, PhD. Dr. Commissiong
discovered MANF from AMBS' proprietary discovery engine PhenoGuard.
AMBS also owns approximately 79.25 million shares of Avant
Diagnostics, Inc. via the sale of its wholly-owned subsidiary
Amarantus Diagnostics, Inc. that occurred in May
2016.
For further information
please visit www.Amarantus.com,
or connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking
Statements
Certain statements, other
than purely historical information, including estimates,
projections, statements relating to our business plans, objectives,
and expected operating results, and the assumptions upon which
those statements are based, are forward-looking statements. These
forward-looking statements generally are identified by the words
"believes," "project," "expects," "anticipates," "estimates,"
"intends," "strategy," "plan," "may," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions.
Forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties which may
cause actual results to differ materially from the forward-looking
statements. Our ability to predict results or the actual effect of
future plans or strategies is inherently uncertain. Factors which
could have a material adverse effect on our operations and future
prospects on a consolidated basis include,but are not limited to:
changes in economic conditions, legislative/regulatory changes,
availability of capital, interest rates, competition, and generally
accepted accounting principles. These risks and uncertainties
should also be considered in evaluating forward-looking statements
and undue reliance should not be placed on such
statements.
Amarantus
Investor and Media Contact:
Ascendant Partners,
LLC
Richard
Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience Holdings,
Inc.